Brown JM - Search Results

1

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR. Singleton RS, et al. Among authors: brown jm. Cancer Res. 2009 May 1;69(9):3884-91. doi: 10.1158/0008-5472.CAN-08-4023. Epub 2009 Apr 14. Cancer Res. 2009. PMID: 19366798

2

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM. Liu SC, et al. Among authors: brown jm. Cancer Res. 2008 Oct 1;68(19):7995-8003. doi: 10.1158/0008-5472.CAN-08-1698. Cancer Res. 2008. PMID: 18829557 Free PMC article.

3

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR. Gu Y, et al. Among authors: brown jm. Mol Cancer Ther. 2009 Jun;8(6):1714-23. doi: 10.1158/1535-7163.MCT-08-1209. Epub 2009 Jun 9. Mol Cancer Ther. 2009. PMID: 19509245

4

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR. Hicks KO, et al. Among authors: brown jm. Clin Cancer Res. 2010 Oct 15;16(20):4946-57. doi: 10.1158/1078-0432.CCR-10-1439. Epub 2010 Aug 20. Clin Cancer Res. 2010. PMID: 20732963 Free PMC article.

5

Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.

Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR. Siim BG, et al. Among authors: brown jm. Cancer Res. 2004 Jan 15;64(2):736-42. doi: 10.1158/0008-5472.can-03-2488. Cancer Res. 2004. PMID: 14744792

6

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.

Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA. Hay MP, et al. Among authors: brown jm. J Med Chem. 2004 Jan 15;47(2):475-88. doi: 10.1021/jm030399c. J Med Chem. 2004. PMID: 14711317

7

Exploiting tumour hypoxia in cancer treatment.

Brown JM, Wilson WR. Brown JM, et al. Nat Rev Cancer. 2004 Jun;4(6):437-47. doi: 10.1038/nrc1367. Nat Rev Cancer. 2004. PMID: 15170446 Review. No abstract available.

8

Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C.

Wu HI, Brown JA, Dorie MJ, Lazzeroni L, Brown JM. Wu HI, et al. Among authors: brown ja, brown jm. Cancer Res. 2004 Jun 1;64(11):3940-8. doi: 10.1158/0008-5472.CAN-03-3113. Cancer Res. 2004. PMID: 15173006

9

Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.

Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, Denny WA, Dewhirst MW, Wilson WR. Hicks KO, et al. Among authors: brown jm. J Natl Cancer Inst. 2006 Aug 16;98(16):1118-28. doi: 10.1093/jnci/djj306. J Natl Cancer Inst. 2006. PMID: 16912264

10

Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.

Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA. Hay MP, et al. Among authors: brown jm. J Med Chem. 2003 Jan 2;46(1):169-82. doi: 10.1021/jm020367+. J Med Chem. 2003. PMID: 12502371

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,089 results

Search Page